Form 4: Acumen CEO Sells Shares for Tax Obligations

Acumen Pharmaceuticals CEO Daniel O'Connell sold shares to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Daniel Joseph O'Connell, Chief Executive Officer and Director of Acumen Pharmaceuticals, Inc. (ABOS), reported sales of common stock.
• On January 21, 2026, O'Connell sold 9,346 shares of common stock at a weighted average price of $1.8112 per share.
• On January 22, 2026, O'Connell sold an additional 2,689 shares of common stock at a weighted average price of $1.8838 per share.
• These sales were executed as 'sell to cover' transactions to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted by O'Connell on June 24, 2024.
• Following these reported transactions, O'Connell beneficially owns 881,275 shares of Acumen Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine "sell to cover" for tax obligations related to RSU vesting, executed under a pre-planned 10b5-1 trading plan. This is a neutral event and does not reflect a change in management's confidence or the company's operational performance.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating adherence to insider trading regulations and pre-planning.
• The sales were specifically for tax withholding obligations related to restricted stock unit vesting, which is a common and routine event for executive compensation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The sales represent the number of shares sold by the Reporting Person through an automatic 'sell to cover' transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive analysis.

Comparison to Industry Standards

• "Sell to cover" transactions for tax obligations upon restricted stock unit (RSU) vesting are standard practice for executives in publicly traded companies across various industries.
• The use of a Rule 10b5-1 plan aligns with best practices for insider trading compliance, demonstrating a pre-planned and non-discretionary approach to stock sales.

Corporate Governance

Stakeholder Impact

• The impact on shareholders is minimal, as these are routine, pre-planned sales for tax purposes and do not signal a change in the company's fundamentals or management's long-term outlook.
• Employees, customers, suppliers, and creditors are unlikely to be directly impacted by this routine insider transaction.

Key Dates

Keywords

Acumen Pharmaceuticals, ABOS, Daniel O'Connell, CEO, Director, Form 4, insider transaction, stock sale, sell to cover, restricted stock units, RSU, 10b5-1 plan, beneficial ownership